神戸大学附属図書館デジタルアーカイブ
論文登録申請
入力補助
English
カテゴリ
学内刊行物
ランキング
アクセスランキング
ダウンロードランキング
https://doi.org/10.24546/81009836
このアイテムのアクセス数:
169
件
(
2026-08-11
08:32 集計
)
閲覧可能ファイル
ファイル
フォーマット
サイズ
閲覧回数
説明
81009836 (fulltext)
pdf
666 KB
100
メタデータ
ファイル出力
メタデータID
81009836
アクセス権
open access
出版タイプ
Version of Record
タイトル
Application of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in Japanese
著者
Suzuki, Misaki ; Tse, Susanna ; Hirai, Midori ; Kurebayashi, Yoichi
著者名
Suzuki, Misaki
著者名
Tse, Susanna
著者ID
A1179
研究者ID
1000070228766
著者名
Hirai, Midori
平井, みどり
ヒライ, ミドリ
所属機関名
医学部附属病院
著者名
Kurebayashi, Yoichi
言語
English (英語)
収録物名
The Kobe journal of the medical sciences
巻(号)
62(6)
ページ
150-161
出版者
神戸大学医学部
Kobe University School of Medicine
刊行日
2016
公開日
2017-05-25
抄録
Tofacitinib(3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile) is an oral Janus kinase inhibitor that is approved in countries including Japan and the United States for the treatment of rheumatoid arthritis, and is being developed across the globe for the treatment of inflammatory diseases. In the present study, a physiologically-based pharmacokinetic model was applied to compare the pharmacokinetics of tofacitinib in Japanese and Caucasians to assess the potential impact of ethnicity on the dosing regimen in the two populations. Simulated plasma concentration profiles and pharmacokinetic parameters, i.e. maximum concentration and area under plasma concentration-time curve, in Japanese and Caucasian populations after single or multiple doses of 1 to 30 mg tofacitinib were in agreement with clinically observed data. The similarity in simulated exposure between Japanese and Caucasian populations supports the currently approved dosing regimen in Japan and the United States, where there is no recommendation for dose adjustment according to race. Simulated results for single (1 to 100 mg) or multiple doses (5 mg twice daily) of tofacitinib in extensive and poor metabolizers of CYP2C19, an enzyme which has been shown to contribute in part to tofacitinib elimination and is known to exhibit higher frequency in Japanese compared to Caucasians, were also in support of no recommendation for dose adjustment in CYP2C19 poor metabolizers. This study demonstrated a successful application of physiologically-based pharmacokinetic modeling in evaluating ethnic sensitivity in pharmacokinetics at early stages of development, presenting its potential value as an efficient and scientific method for optimal dose setting in the Japanese population.
カテゴリ
医学部附属病院
The Kobe journal of the medical sciences
>
62巻
>
62巻6号(2016)
紀要論文
関連情報
URI
http://www.med.kobe-u.ac.jp/journal/contents.html
詳細を表示
資源タイプ
departmental bulletin paper
ISSN
0023-2513
OPACで所蔵を検索
CiNiiで学外所蔵を検索
NCID
AA00711740
OPACで所蔵を検索
CiNiiで表示
ホームへ戻る